Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Establishes JV With India's Sun Pharma To Develop Novel Combinations Of Branded Generics For Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Merck & Co. is establishing a joint venture with India's Sun Pharmaceutical Industries Ltd. for a broad-based alliance to develop, manufacture and commercialize novel combinations and "incrementally innovative" branded generics in emerging markets, the two companies announced April 11
Advertisement

Related Content

PharmAsia News Presents: Notable Notes On Emerging Markets (Vol. 1, No. 2)
Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 1 of 2)
Asia Spotlight: Innovative, Differentiated Generics To Lead Merck Into Emerging Markets, Says EM President Kevin Ali
Innovative, Differentiated Generics To Lead Merck Into EMs, Says Merck EM President Kevin Ali; Prefer Partners Over Buyouts
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
Emerging Views On Emerging Markets: The Sanford Bernstein Strategic Decisions Conference
Merck, Cipla Deny Deal Talks But The Charm Of The Indian Market Stokes Speculations
Pfizer, Merck Execs Share Emerging Markets Strategies - Windhover's Pharmaceutical Strategic Alliances Conference (Part 2 of 2)
Pfizer, Merck Execs Share Emerging Markets Strategies - Windhover's Pharmaceutical Strategic Alliances Conference (Part 2 of 2)
Novartis Aims Double Edged Attack With Galvus And Jalra To Take On Merck's Januvia In India
Advertisement
UsernamePublicRestriction

Register

SC077624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel